InfuSystem reports FY2023 record revenue $125.8M, +14%; EPS $0.04; guides FY2024 high-single-digit growth

InfuSystem Holdings, Inc

FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).
Q4 net revenue $31.8M (+10%); net income $0.1M ($0.00 diluted EPS) vs $0.1M ($0.01) prior year.
Adjusted EBITDA $22.4M (+8%); operating income $4.1M (+147%); net income $0.9M vs $0.0M prior year.
FY2024 guidance: high-single-digit revenue growth; Adjusted EBITDA margin in high-teens (above 17.8%).
Joint venture SI Wound Care (with Sanara MedTech) expected to generate meaningful revenue in 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2023 results: revenue Net revenues totaled $125.8 million. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2023
Revenue: Net revenues totaled $125.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $49.2 million, increases of 11% and 20% Adjusted EBITDA (non-GAAP): $22.4 million, an 8%

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

InfuSystem Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-011061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.